Unresectable Melanoma
📧 Sign up to get email alerts when something new happens for Unresectable Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]
Phase 2 trial evaluating rigosertib in combination with pembrolizumab for unresectable or metastatic melanoma that is refractory to PD-1 inh…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) [Phase 2]
A Phase 2 trial evaluating Acasunlimab alone and in combination with pembrolizumab for advanced melanoma that has relapsed after prior check…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. [Phase 3]
Phase 3 trial evaluating lifileucel plus pembrolizumab versus pembrolizumab alone in untreated advanced melanoma (metastatic/unresectable); …
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of the IL-6 receptor inhibitor sarilumab with ipilimumab, nivolumab, and relatlimab f…
-
CLINICAL_TRIALS research · 2025-08-28Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) [Phase 3]
Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in advanced/metastatic/unresectable melano…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-01-07Clinical Trial Update: Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors [Phase 1]
A Phase 1 trial of Nab-Paclitaxel in combination with STI-3031 Complex (AP160-Complex) for advanced or metastatic solid tumors has been with…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma [Phase 3]
A Phase III randomized trial comparing the PD-1 inhibitor JS001 (toripalimab) to dacarbazine as first-line therapy for unresectable or metas…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations [Phase 1]
Phase 1 bioequivalence study comparing Binimetinib 3 x 15 mg formulation with a 45 mg formulation in melanoma patients with BRAF V600 mutati…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 trial evaluating lifileucel with reduced-dose fludarabine/cyclophosphamide lymphodepletion and interleukin-2 for unresectable or met…
-
CLINICAL_TRIALS trial_result · 2023-12-22Clinical Trial Update: A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 study evaluating sotigalimab (APX005M) in unresectable or metastatic melanoma has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-05-01Clinical Trial Update: Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma [Phase 2]
A Phase 2 study compares the combination of ipilimumab and nivolumab versus ipilimumab alone in advanced melanoma, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) [Phase 2]
Phase 2 clinical trial update for INCMGA00012 in selected solid tumors, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC [Phase 1, Phase 2]
Phase Ib/II trial evaluating fecal microbiota transplant in combination with nivolumab for metastatic or inoperable melanoma and NSCLC; stat…
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer [Phase 1, Phase 2]
Phase 1/2 trial update of uprosertib combined with dabrafenib and trametinib in patients with stage IIIC-IV melanoma (cutaneous/metastatic/u…
-
CLINICAL_TRIALS trial_result · 2020-09-07Clinical Trial Update: LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [Phase 2]
Phase II open-label trial evaluating dabrafenib plus trametinib in unresectable stage III/IV BRAF-mutant melanoma; study completed with post…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating nab-paclitaxel with bevacizumab or ipilimumab as first-line therapy in patients with unresectable stage IV melanoma…
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) [Phase 3]
Phase 3 trial comparing BMS-936558 (nivolumab) to physician's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy; trial comp…
-
CLINICAL_TRIALS trial_result · 2016-03-16Clinical Trial Update: An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma [Phase 2]
Phase 2 open-label trial of lenvatinib in previously treated patients with unresectable stage III or stage IV melanoma completed; results po…